Mouse Anti-Human Spastin Monoclonal Antibody, Unconjugated, Clone Sp 3G11/1 from Santa Cruz Biotechnology, Inc.
mCD-1 Multi-Probe Template Set from BD Biosciences Pharmingen
Custom Immunization from Proteintech Group, Inc.
Rat Anti-Mouse VCAM-1 / CD106 Monoclonal Antibody, Unconjugated, Clone 112702 from R&D Systems
Biology Products:(Date:12/2/2009)... , QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ -...(the "Company"), a global biopharmaceutical compan... announced that the U.S. Food and Drug Administrat...he Company,s PI3K/Akt pathway inhibitor compound, ...ed/refractory multiple myeloma. Keryx Biopharmaceu...
(Date:12/1/2009)..., INCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-Fir...I ) today announced revenue guidance for the fourt... $57 million, as compared with $69 million for the...r 2008 results was the first of two installment pa...ed in fourth quarter 2008 results was a one-time $...
(Date:12/1/2009)... , CAMBRIDGE, Mass., Dec. 1 /PRNewswire/...ogy industry and to promote its potential, a group...ion of the Synthetic Biology Industry Association ...e goal of the association is to provide a forum fo...the new industry, address its opportunities and it...
(Date:12/1/2009)... , SAN FRANCISCO, Dec. 1 The Bu...most half the value it lost in October. The Select...xcellent month for the general markets with the Do...value. The gains held firm in the final two tradin... sluggish Thanksgiving holiday shopping and Dubai,...
Breaking Biology Technology:AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Biotech Gets Back on Track in November 2Biotech Gets Back on Track in November 3Biotech Gets Back on Track in November 4